NOVACHECK SARS-CoV-2 Covid-19 Antigen Rapid Test Package Inser

(For Professional use only

INTENDED USE

SARS-CoV-2 Antigen Rapid Test is intended for the qualitative in vitro detection of SARS-CoV-2 Antigen in either anterior nasal, oronharvnegal or

SUMMARY

The SARS-CoV-2 is an enveloped β-coronavirus circular or elliptical particle diameter of about 60 ~ 140nm often pleomorphic obviously different from SARS-The SPRS-COV-2 is an introduce protonomous the characteristics. The main clinical manifestations include fever, faigue and other systemic symptoms, accompanied by dry cough, dyspnea, etc., which can rapidly develop into severe pneumonia, respiratory failure, acute respiratory distress syndrome, septic shock, multi-organ failure, severe acid-base metabolism disorder, and even life-threatening. SARS-CoV-2 has been identified as the main means of transmission through respiratory droplets (sneezing, coughing, etc.) and contact (picking nostril with the hand in contact with the virus, rubbing eyes, etc.).

SARS-CoV-2 is sensitive to ultraviolet ray and heat, and can be inactivated at 56°C for 30 minutes and by fat soluble solvent such as ethyl ether, 75% ethanol, chlorine disinfectant, peracetic acid and chloroform

PRINCIPLE

SARS-CoV-2 Antigen Rapid Test employs immuno-lateral chromatography technology for the qualitative detection of artigens. The colloidal gold particles labeled with the anti-SARS-CoV-2 antibody 1 are fixed on the conjugation pad. The anti-SARS-CoV-2 antibody 2 is bound on the "T" test line of nitrocellulose membrane. The Goad Anti-Mouse [gd is bound on the "C" control line of nitrocellulose membrane. When the concentration of SARS-CoV-2 in the specimen is higher than the minimum detection limit, which can conjugate with the anti-SARS-CoV-2 antibody 1 labeled with colloidal gold paticles to form a complex. This complex migrates on the membrane via capillary action until the test line, where it will be captured by the anti-SARS-CoV 2 antibody 2 antibody 2 bound on the test line, forming "Ant-Anti-SARS-CoV 2 antibody I-SARS-CoV 2. AntibSARS-CoV 2 antibody 2 complex. These complexes are deposited to display color as the determination of antigen positive, the rest of anti-SARS-CoV-2 antibody 1 labeled with colloidal gold particles conjugate with the Goat Anti-Mouse IgG and deposit to display color as the determination of quality of the "C" control line. When the concentration of SARS-CoV-2 in the specimen is lower than the minimum detection limit or no SARS-CoV-2, the complexes only deposit and display color in the "C" control line.

KIT COMPONENTS

Cassette type:

Timer

1 test/kit, 5 tests/kits, 10 tests/kits, 20 tests/kits, 25 tests/kits, 50 tests/kits, 100 tests/kits, 200 tests/kits, Test Device: mouse anti-SARS CoV-2 monoclonal antibody, goat anti-mouse $I_{2}G$ polyclonal antibody, nitrocellulose membrane - Extraction solution and tubes: phosphate buffer solution (0.01 M, pH 7.4 ± 0.2)

Instructions for use - Single-use swab (applicable as nasal, oropharyngeal or nasopharyngeal swab).

MATERIALS REQUIRED BUT NOT PROVIDED

REAGENT STORAGE AND STABILITY

Store the kit at 2-30°C/36-86°F, out of direct sunlight, valid for 24 months. Do not freeze the kit. The test device should be used within 60 minutes after opening the foil pouch. For production date and expiration date, please refer to the product label.

SPECIMEN REQUIREMENTS


1. Specimen collec

Anterior nasal swab:



Insert the sterile swab into the anterior nasal section and rotate the swab 3 times along the inner wall of the nasal cavity. Repeat the procedure on the other side. Then remove the swab

Oropharyngeal swab specimen collection:



Nasopharyngeal swab specimen collection:

Gently hold the patient's head with one hand, carefully insert the swab into the nostril and slowly go deep along the bottom of the lower nasal passage. When the top of the swab reaches the back wall of the nasopharyngeal cavity, gently rotate it for one round (pause for a moment once reflex cough), and then slowly remove the swab.

After treatment, the specimens can be stored at room temperature (15-30°C) for up to 24 hours, at 2-8°C for up to 72 hours and at -20°C for up to 36 months. The specimens are allowed to be frozen and thawed for three times

ASSAY PROCEDURE

Before using the reagent, operate it strictly according to the package insert to ensure the accuracy of the results

The fresh specimens shall be treated with extraction solution as soon as possible after collection, but no later than 1 hour after collection. 2. Test device, sample and instrument must be at room temperature (15~30°C) during the testing.

Sample preparation

n storage

- Remove one specimen extraction tube from the kit before testing. Label one specimen extraction tube or write specimen number on it.
- Place the labeled specimen extraction tube in a rack in the designated area of the workspace.
- There is approximately 1 ml of liquid in the extraction solution bottle, dip the sample stick into this tube. Dip the swab head into the extraction solution in the extraction tube and rotate the swab close to the specimen extraction tube wall for about 10 seconds or 10 times to dissolve the specimens in the solution as month as possible.
- 6. Squeeze the tip of the symbol and the same wall of the same extraction tube to keep the liquid in the tube as much as possible, break the swab at the breaking point and lock it inside the tube. then cap the tube.
- Add 3 drops to the place marked S on the test kit, then wait 15 minutes.
- ψ̈́ 6

Sample detection

- Before the detection, the test device and the sample are taken out from the storage condition and balanced to room temperature (15-30°C). Tearing the packaging of the aluminum foil pouch, take out the test device, and place it horizontally on the test tab
- Vertically invert the specimen extraction tube (the extraction tube with processed specimens), add 3 drops vertically into the sample well of the test device
- venteany invert me specimien extraction tube (the extraction tube with processed specimens). The test results should be interpreted within 15 to 20 minutes, invalid If more than 30 minutes. Please interpret the result by visual inspection.

POSITIVE VALUE/LIMIT OF DETECTION

Positive value/limit of detection: 1.7×102 TCID@/mL

Select the confirmed inactivated SARS-CoV-2 medium, (concentration 3.4×10⁵ TCID₅₀/mL), use gradient dilution method to find out the virus medium to reach the critical value of the detection. Repeat the action for 20 time and the test result is positive for at least 19 times.

INTERPRETATION OF TEST RESULTS

Positive: Two lines appear. A colored one Line appears in the control area (C) and another colored line



appears in the Test area (T) regardless of strength the test line.

Negative

A colored line appears in the Control area (C) and no line appears in the test area (T)

Invalid



The control line is not displayed. Insufficient sample volume or a wrong procedure / handling are the most likely reasons for not Appearance of the control line. Check the procedure and repeat that Test with a new test kit. If the problem persists, exit the use the batch immediately and contact your local dealer,

Note: The color of the test strip will vary with different samples. However, regardless of the color of the test strip, it should be judged as positive result within the specified detection time

LIMITATION

- 1. The SARS-CoV-2 Antigen Rapid Test is for in vitro diagnostic use only. The test should be used for the detection of SARS-CoV-2 Antigen in oropharyngeal swab and nasopharyngeal swab specimens only.
- This test kit can only be used for the qualitative detection of SARS-CoV-2 antigens, and can't determine the quantity of SARS-CoV-2 antigens in samples If the test result is negative and clinical symptoms persist. It is recommended to repeat sampling or use other testing methods for testing. A negative resu cannot preclude the possibility of exposure to or infection with SARS-CoV-2 virus at any time
- 4. The test results of the test kits are for clinicians' reference only, and should not be used as the only basis for clinical diagnosis. The clinical management of patients should be comprehensively considered in combination with their symptoms/signs, medical history, other laboratory tests and treatment responses,
- 5. Due to the limitation of the detection reagent methodology, the limit of detection of this reagent is generally lower than that of nucleic acid reagents. Therefore, the test personnel should pay more attention to the negative results and need to combine other test results to make a comprehensive judgment. It is recommended to use nucleic acid testing or virus isolation and culture identification methods to review negative results which have doubts.
- 6. Analysis of the possibility of false negative results:
- (1) Unreasonable specimen collection, transportation and processing, low virus titer in the sample, no fresh sample or freezing and thawing cycling of the sample may lead to false negative results
 - may read to rate negative results. (2) The mutation of viral gene may lead to changes in antigenic determinants, which lead to negative results. (3) The results of the SARS-CoV-2 has not been completely thorough; the virus may mutate and cause the differences for best sampling time (virus titer peak)
 - and sampling location. Therefore, for the same patient, we can collect samples from multiple locations or follow up for multiple times reduce the possibility

CLINICAL PERFORMANC The test results of NOVACHECK SARS-CoV-2 Covid-19 Antigen test and the PCR test results are shown in the following table

		PCR test results		Total
		Positive(+)	Negative(-)	
Test reagent	Positive(+)	159	0	159
results	Negative(-)	4	257	261
Total number		163	257	420

Sensitivity: 97.54%; (95%CI: 93.86%~99.04%) Specificity:100 %; (95%CI: 98.53%~100%) Total clinical coincidence rate: 99.11%. (95%CI: 97 42%~99 70%

PERFORMANCE CHARACTERISTICS

Using enterprise reference for testing, the results meet the requirements of enterprise reference

Cross reaction

Name	Concentration	Test result
Influenza B/Y amagata	1.00×10 ² TCID ₅₀ /mL	Negative
Influenza B/Voctoria	1.07×105 TCID ₅₀ /mL	Negative
Influenza A H1N1	1.00×10 ² TCID ₅₀ /mL	Negative
Influenza A H3N2	1.15×10 ² TCID ₅₀ /mL	Negative
Adenovirus 3	1.24×10 ⁵ TCID ₅₀ /mL	Negative
Adenovirus 7	1.87×106 TCID ₅₀ /mL	Negative
Human coronavirus 229E	1.00×105 TCID ₅₀ /mL	Negative
Human coronavirus OC43	2.00×106 TCID ₅₀ /mL	Negative
Human coronavirus NL63	2.00×106 TCID ₅₀ /mL	Negative
MERS-coronavirus	2.00×106 TCID ₅₀ /mL	Negative
Cytomegalovirus	1.00×10 ⁵ TCID ₅₀ /mL	Negative
Enterovirus 71	2.55×10 ⁵ TCID ₅₀ /mL	Negative
Human parainfluenza virus 1	1.35×105 TCID50/mL	Negative
Human parainfluenza virus 2	6.31×10 ⁵ TCID ₅₀ /mL	Negative
Human parainfluenza virus 3	3.25×105 TCID50/mL	Negative
Measles virus	6.31×10 ⁵ TCID ₅₀ /mL	Negative
Mumps virus	6.31×106 TCID ₅₀ /mL	Negative
Respiratory syncytial virus	2.00×105 TCID ₅₀ /mL	Negative
Rhinovirus 1A	1.26×105 TCID ₅₀ /mL	Negative
Bacillus pertussis	1.30×106 CFU/mL	Negative
Chlamydophila pneumoniae	1.00×105 CFU/mL	Negative
Escherichia coli	1.00×105 CFU/mL	Negative
Haemophilus influenzae	1.20×106 CFU/mL	Negative
Mycobacterium binding	1.00×10 ⁵ CFU/mL	Negative
Mycoplasma Pneumoniae	1.00×106 CFU/mL	Negative
Neisseria meningococcus	1.00×105 CFU/mL	Negative
Neisseria gonorrhoeae	1.00×105 CFU/mL	Negative
Pseudomonas aeruginosa	3.70×106 CFU/mL	Negative
Staphylococcus aureus	2.20×106 CFU/mL	Negative
Streptococcus pneumoniae	1.00×10 ⁶ CFU/mL	Negative

Streptococcus pyogenes		1.28×106 CFU/mL		Negative	
Streptococcus salivarius	1.00×10 ⁵ CFU		/mL Negative		
erfering Substance					
Interfering substance name	Concentration	Negative interference result		Positive interference result	
Mucin	5%	Negative		Positiv	/e
Whole blood	5% (V/V)	Negative		Positive	
α-interferon	500 thousand IU/mL	Negative		Positive	
Zanamivir	500ng/mL	Negative		Positive	
Ribavirin	20µg/mL	Negative		Positiv	/e
Oseltamivir	5µg/mL	Negative		Positiv	/e
Peramivir	0.2mg/mL	Negative		Positiv	/e
Lopinavir	8 mg/mL	Negative		Positiv	/e
Ritonavir	530µg/mL	Negative		Positiv	/e
Umifenovir	4µg/mL	Negative		Positiv	/e
Levofloxacin	30µg/mL	Negative		Positiv	/e
Azithromycin	4.5µg/mL	Negative		Positiv	/e
Ceftriaxone	0.8mg/mL	Negative		Positiv	/e
Meropenem	1.1mg/m1	Negative		Positiv	/e
Tobramycin	4ng/mL	Negative		Positiv	/e
Phenylephrine	20µg/mL	Negative		Positiv	/e
Oxymetazoline	0.1mg/mL	Negative		Positiv	/e
Beclomethasone	0.1mg/mL	Negative		Positiv	/e
Dexamethasone	2 mg/mL Negative			Positiv	ie.

2 mg/mL Negativ Flunisolide 0.1mg/mL Negative Positive Triamcinolone acetonide 10.5ng/mL Negative Positive Budesonide 2.75ng/mL Negative Positive Mometasone 10ng/mL Negative Positive Fluticasone 55µg/mL Negative Positive Histamine Hydrochloride 10ng/mL Negative Positive Sodium chloride Negative Positive 5%

Within the concentration of 3.4×105 TCID₅₀/mL for cell culture medium of SARS-CoV-2 antigen, the test results of this product showed no Hook effect.

Inte

- 1. The sample should be tested in the laboratory with certain conditions. All samples and materials in the testing process shall be handled in accordance with the laboratory practice for infectious diseases.
- The kit shall be stored in strict accordance with the conditions specified in this package insert. Please use it within the validity period.
- 3. Do not open the sealed pouch until you are ready to perform a test. The kit should be sealed and protected against moisture. If the foil pouch is damaged or damp, stop using it immediately
- 4. Specimen collection and detection should be performed accordance with the package insert strictly.

ile symbol					
	Do Not Reuse	In Vitro Diagnostic Medical Device			
	att Store at 2-30°C	Consult Instructions For Use			
	LOT Batch code	Contains sufficient for < n> tests			
	Use-by Date	away from direct sunlight			
	Stay dry	Don't use if that Package is damaged			
	Manufacturer	production date			



Novatech Tıbbi Cihaz Ürünleri Sanavi ve Ticaret A.S.


2.Organize Sanayi Bölgesi Hacı Sani Konukoğlu Bulvarı 83228 Nolu Cadde No:17 Şehitkamil/Gaziantep/TURKEY Tel:+90 342 502 27 27

Fax:+90 342 503 01 30 www.novadiag.con

"Novacheck" Brand Novatech Medical Device Products Industry and Trade Inc. is a registered trademark of the company.

Rev Date:17.12.2021 Rev Number:02





Index of the symbol